Company Overview - Caris Life Sciences has a comprehensive oncology database with over 1,016,000 molecular profiles[5] - The company has a global presence with over 1,800 employees[7] - Caris has established a Precision Oncology Alliance (POA) with 99 leading cancer centers[5] Data and Technology - The company has profiled over 1 million cases in its genomic dataset[9] - Caris possesses over 627,000 whole exomes and 678,000 whole transcriptomes[9, 11] - The company has access to over 740,000 profiles with matched molecular data and clinical outcomes[11] Market Trends and Reach - Cancer centers are standardizing molecular profiling towards technology and service leaders[13] - Caris has a field-based team of approximately 250 and 50 MSLs serving over 6,000 oncologists in the US[18] - The company has integrated ordering locations in over 3,350 EHRs[18] Financial Performance - Caris achieved $281 million in revenue in Q4 2025, representing a 116% year-over-year growth[35, 67] - The company's total revenue increased to $800 million in FY 2025, a 94% increase year-over-year[69] - Molecular profiling services revenue increased to $755 million, a 116% increase year-over-year[69]

IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient- centric, next-generation AI TechBio company and precision medicine pioneer, today announced a partnership with Everlywell, a digital health company pioneering the next generation of biomarker intelligence, combining AI-powered technology with human insight to deliver personalized, actionable health answers. Caris expects to launch the Caris Detect assay in the first half of 2026. About Caris Life Sciences Ca ...